Standard BioTools Provides Update on Sale of Mass Cytometry Business
Key Highlights
- ➤Element Biosystems to acquire Mass Cytometry business for $5.5 million cash at closing
- ➤Standard BioTools (LAB) terminates Multiplex Bio agreement after Element proposal deemed superior
- ➤Element transaction increases LAB net cash for Treeline exchange ratio by approximately $15 million
- ➤Element transaction expected to close by end of 2026, subject to stockholder approval
- ➤Treeline transaction also expected to close by end of 2026, subject to stockholder approval
Expert Statements
Michael Egholm, President and Chief Executive Officer of Standard BioTools
“We are pleased to realize greater value for our stockholders, while ensuring continuity for our Mass Cytometry customers and team. The competitive interest in this business only underscores the strength of our CyTOF, Hyperion, and Maxpar products, and the meaningful role they play in advancing single cell and spatial biology research.”
Tom Claugus, Founder of GMT Venture
“We see significant long-term value in the Mass Cytometry business. It is built on foundational technology with an exceptional customer base and a dedicated team. We believe deeply in the long-term potential of the CyTOF and Hyperion platforms, and are committed to providing the resources needed to support the team, serve customers without interruption, and invest in the next generation of these products. We look forward to working closely with the team to build on this legacy.”
BOSTON, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):
Standard BioTools terminated its previously announced agreement to sell its Mass Cytometry Business to Multiplex Bio and entered into a definitive agreement to sell its Mass Cytometry business to Element Biosystems, LLC (“Element”), an acquisition vehicle formed by GMT Venture Partners, LLC ("GMT Venture") for $5.5 million in cash payable at closing, subject to customary adjustments.
Get started
Create a free account to read the full story.